NEW
YORK, Sept. 9, 2015 /PRNewswire/ -- Dementia refers to a group of mental
disorders that causes progressive decline in the intellectual functioning of a
person.
The
precise cause of dementia is unknown and it depends upon the type of mental
disorder a person is suffering from. Dementia is one of the major causes of
disability among the elderly population.
In
addition, with the rise in aging population, the proportion of patients with
neurodegenerative diseases is also surging. The treatment of movement disorder
and dementia depends upon the cause of the disease.
It
is treated symptomatically with the help of biological therapy and medications
such as small molecules.
In
addition, awareness about mental diseases has risen in various parts of the
world owing to growing investments and initiatives undertaken by private and
public health institutions.
Increasing
prevalence of neurodegenerative disorders, rising awareness about mental
diseases, and growing R&D investments in drug discovery and developments
are the key driving factors of the treatment for syndromes of dementia and
movement disorders market.
On
the other hand, strict regulatory requirement and long approval time for drugs,
and lack of comprehensive therapeutic management of dementia and movement
disorders are major concerns for the market.
In
addition, most of the drugs fail in Phase III due to lack of sufficient
knowledge about the mechanisms of the brain and the unknown causes of the
disease. Rising number of collaborations and partnerships is the major trend in
the market leading to rise in discovery and development of dementia and
movement disorder drugs.
North
America dominates the global market for treatment for syndromes of dementia and
movement disorders due to large number of aging population and increasing
incidence of neurodegenerative diseases.
Asia
is expected to show high growth rates in the next five years in the global
treatment for syndromes of dementia and movement disorders market.
Some
of the key driving forces for treatment for syndromes of dementia and movement
disorders market in emerging countries are increasing geriatric population,
large pool of patients and rising awareness of mental disorders. In addition,
various initiative programs are organized to improve the status of awareness
about dementia and movement disorders.
This
report provides in-depth analysis and estimation of the treatment for syndromes
of dementia and movement disorders market for the period 2014 to 2020,
considering 2013 as the base year for calculation.
In
addition, data pertaining to current market dynamics, including market drivers,
restraints, trends, and recent developments, has been provided in the report.
The
treatment for syndromes of dementia and movement disorders market is
categorized on the basis of the drugs used to treat progressive dementia, drugs
used to treat progressive dementia with neurological abnormalities, drugs used
to treat movement disorder syndromes, and geography.
Based
on drugs used to treat progressive dementia, progressive dementia with
neurological abnormalities and movement disorder syndromes the market comprises
of disease based therapeutics and drug category.
On
the basis of geography, the report identifies and analyses the market size and
predictions for North America, Europe, Asia, and Rest of the World (RoW).
Some
of the major players in the treatment for syndromes of dementia and movement
disorders market are F. Hoffmann-La Roche, Ltd., Novartis AG, Merck & Co.,
Inc., Sanofi S.A., Valeant Pharmaceutical International, Inc., AstraZeneca GmbH
and Pfizer, Inc.
These key market players have been profiled on the basis of
attributes such as company overview, recent developments, growth strategies,
sustainability, and financial overview.
Read
the full report: http://www.reportlinker.com/p03175821-summary/view-report.html
About
Reportlinker
ReportLinker
is an award-winning market research solution that finds, filters and organizes
the latest industry data so you get all the market research you need -
instantly, in one place.
No comments:
Post a Comment